ALK and neuroblastoma: Taken together, these data strongly suggest that combined inhibition of ALK and MDM2 in TP53 wild-type neuroblastoma with ALK aberrations may provide an effective therapeutic modality capable of preventing as well as overcoming the resistance observed with the ALK inhibitor monotherapy.